RMD ResMed Inc.

ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum

ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast.

More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days.

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investorsFor media
Amy WakehamJayme Rubenstein
+1 858.836.5000+1 858.836.6798



EN
15/03/2023

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 202...

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025 SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location: •Date:Thursday, October 30, 2025 •Time:1:30 p.m. PD...

October 9, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Participation in the Bank of America Global Healthcar...

Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay w...

September 16, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Pr...

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of , a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and healt...

September 3, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adul...

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in projecting a significant rise in obstructive sleep apnea (OS...

August 27, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awar...

Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its  nasal cradle mask won two prestigious : Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed...

August 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch